Ritonavir, also known as Norvir, is a type of medicine called a protease inhibitor (PI). PIs act by blocking protease, a protein that HIV needs to make more copies of itself. Ritonavir was approved by the FDA on March 1, 1996, for use with other antiretroviral agents in the treatment of HIV infection in adults and children 2 years of age or older. Ritonavir is now approved with other anti-HIV drugs in the treatment of HIV-1 infection in children in individuals over 1 month in age. Studies have shown that ritonavir works as a booster for some other PIs. Taking ritonavir makes it possible to take a lower dose of the other PIs. This medicine does not cure or prevent HIV infection or AIDS and does not reduce the risk of passing the virus to other people.
A recent paper describes the use of aprotinin, a protease inhibitor that works across several pathways, to reduce the severity of COVID-19.
Researchers assessed the coronavirus disease 2019 (COVID-19) rebound in untreated COVID-19 infections.
Researchers estimated the impact of different COVID-19 mRNA booster vaccinations in the United States during fall 2022.
When President Joe Biden tested positive for covid-19 on July 21, his physician recommended he take the antiviral drug Paxlovid.
Researchers reported mutations in SARS-CoV-2 Delta and Omicron variants of concern infection cases treated with neutralizing monoclonal antibodies.
A recent study reviewed the existing treatment modalities, including vaccines and antivirals, for SARS-CoV-2 infection.
In a recent study published in the bioRxiv* preprint server, researchers at the Medical University of Innsbruck assessed the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) 3CLpro mutations responsible for Paxlovid resistance. The 3-chymotrypsin-like protease (3CLPro), or main protease (Mpro), is the main protease found in coronaviruses.
In a recent article posted to the bioRxiv* preprint server, researchers at Rutgers, the State University of New Jersey, the University of South Florida, and the Catholic University of America demonstrated that the natural severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) main protease (Mpro) mutations result in nirmatrelvir resistance.
Researchers assess the activity of all potential mutations in the SARS-CoV-2 3CLpro.
Researchers assessed the in vivo effectiveness of monoclonal antibodies and directly acting antiviral agents against the SARS-CoV-2 Omicron BA.1 and BA.2 sublineages.
In a recent Morbidity and Mortality Weekly Report (MMWR) published on the United States Center for Disease Control and Prevention (US-CDC) website, researchers described cases of coronavirus disease 2019 (COVID-19)–related hospitalizations and emergency department (ED) visits in five to 15 days following Paxlovid (Nirmatrelvir/ritonavir ) treatment.
Paxlovid is the leading oral medication for preventing severe cases of COVID-19 in high-risk individuals.
In a recent study posted to the medRxiv* pre-print server, researchers investigated the effectiveness of nirmatrelvir plus ritonavir in preventing hospitalizations among individuals aged 50 or older and vaccinated for coronavirus disease 2019 (COVID-19).
Researchers hypothesized that the emergence of resistant SARS-CoV-2 variants can be anticipated by identifying possible escape mutations already present in the existing SARS-CoV-2 populations.
Researchers surveyed a representative sample of the adult population of New York City, United States, to determine the prevalence of COVID-19.
Researchers assessed the effectiveness of two orally administered antiviral medications, nirmatrelvir/ritonavir, and molnupiravir, in decreasing hospitalization and deaths among real-world non-hospitalized COVID-19 patients in Hong Kong.
Insilico Medicine, a clinical-stage end-to-end artificial intelligence (AI)-driven drug discovery company, today announced its nomination of a novel preclinical candidate (PCC) targeting 3C-like (3CL) protease for the treatment of COVID-19.
In a recent study posted to the medRxiv* pre-print server, researchers evaluated the effectiveness of oral severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antivirals, molnupiravir (Lagevrio) or nirmatrelvir/ritonavir (Paxlovid) in a real-world setting.
In a recent study posted to the bioRxiv* pre-print server, researchers from Belgium evaluated the efficacy of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antiviral drugs in a severe combined immunodeficient (SCID) mouse model.
A new study discusses the safety and efficacy of the COVID-19 vaccination and potential strategies to optimize protection in patients with impaired immunity.